Effects of balloon pulmonary angioplasty on cardiac and pulmonary functions and complications in patients with chronic thromboembolic pulmonary hypertension
Abstract
Objective: To explore the effects of balloon pulmonary angioplasty (BPA) on cardiac and pulmonary functions and complications in patients with chronic thromboembolic pulmonary hypertension (CTEPH).
Methods: From February 2023 to December 2024, 100 patients with CTEPH at our hospital underwent BPA treatment were selected. The WHO cardiac function classification, right heart catheterization parameters, cardiac function indexes, levels of NT-proBNP, TNF-α and IL-6, exercise tolerance, pulmonary function indexes, pulmonary artery pressure, and blood gas indexes were compared before BPA and 3 months after the last BPA. The BPA-related complications were recorded.
Results: Compared with before BPA, the WHO cardiac function classification of Grade I, Grade II and Grade III was significantly improved 3 months after the last BPA (p = 0.003, p = 0.020, p = 0.000), the mPAP and PVR were significantly lower (p p p p p p p α and IL-6 were significantly lower, the PaO2 level was significantly higher (p 2 level was significantly lower (p p > 0.05). In addition, there were 5 cases of hemoptysis, 1 case of reperfusion pulmonary edema, and no other complications occurred.
Conclusion: BPA can improve the exercise tolerance, cardiac and pulmonary functions, and blood gas level of patients with CTEPH, and the incidence of complications is relatively low. However, due to the limitations of the single-arm design, the results of this study need to be further verified through randomized controlled…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.